Recurrent Melanoma Recruiting Phase 1 / 2 Trials for Nivolumab (DB09035)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02304458Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasTreatment